CDKN2A and melanoma: Genetic studies have identified common mutations in melanoma, including cyclin-dependent kinase inhibitor 2A (CDKN2A), neuroblastoma rat sarcoma viral oncogene homolog (NRAS), phosphatase and tensin homolog (PTEN), and BRAF, with the latter being the most frequent oncogenic mutation.